Select Journal or Resource JAMA & Archives Home JAMA Archives of   Dermatology   Facial Plastic Surgery   Family Medicine (1992-2000)   General Psychiatry   Internal Medicine   Neurology   Neurology and Psychiatry (1919-1959)   Ophthalmology   Otolaryngology—Head & Neck Surgery   Pediatrics & Adolescent Medicine   Surgery JAMA & Archives CME Calendar of Events JAMA Career Center For The Media JAMAevidence AMA Manual of Style Peer Review Congress JAMA-français

	Institution: CLOCKSS  | My Account | E-mail Alerts | Access Rights | Sign In Vol. 7 No. 3, May 1998   Archives  • Online Features  Article Links  • Return to Article Downloading the PowerPoint slide may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it. Copyright restrictions may apply. Please see our Conditions of Use. Figure 2. Percentage of patients with no or mild clinical disability 60 or 120 minutes after dosing with sumatriptan hemisulfate nasal spray (5, 10, or 20 mg) or placebo. Asterisk indicates P<.05 vs placebo; dagger, P<.05 vs 5 mg of sumatriptan hemisulfate nasal spray. HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | HELP CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP   © 2011 American Medical Association. All Rights Reserved.